| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/11/2006 | US20060100254 Thiazolyl-dihydro-indazole |
| 05/11/2006 | US20060100253 Novel compounds for the treatment of neurological disorders |
| 05/11/2006 | US20060100252 Beta 3 adrenergic receptor agonists; pollakiuria or urinary incontinence; antiulcer, overactive bladder, pancreatitis, obesity, diabetes, insulin resistance, hypertriglyceridemia, hypercholesterolemia, tocolytic agents; 4'-[2-(2-hydroxy-2-phenylethyl]amino]ethyl]-4-biphenylyl]acetic acid |
| 05/11/2006 | US20060100251 Substituted phenylalkanoic acids |
| 05/11/2006 | US20060100249 Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses |
| 05/11/2006 | US20060100248 alleviating vision defects, multiple sclerosis, neurodegenerative diseases, stroke, spinal cord injury, Alzheimer's disease, Parkinson's disease or pain, comprising administering sodium channel modulators comprising pyrazole or indazole derivatives, such as 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole |
| 05/11/2006 | US20060100247 Treatment of diabetes with thiazolidinedione and metformin |
| 05/11/2006 | US20060100246 Synthesis of I kappa B kinase beta inhibitors that are 2-amino-4,6-disubstituted nicotinic acid ester analogs, by reacting an aryl ketone, an aldehyde and a cyanoacetate with an ammonium salt |
| 05/11/2006 | US20060100245 Substituted biphenyl-4-carboxylic acid arylamide analogues |
| 05/11/2006 | US20060100244 Such as (3-chloro-4-fluorophenyl)(4-fluoro-4-{[(5-hydoxypyridin-2-ylmethyl)amino]methyl}piperidin-1-yl)methanone; serotonin receptor agonists; for treating depression, pain, and substance abuse |
| 05/11/2006 | US20060100243 Methylphenidate analogs and methods of use thereof |
| 05/11/2006 | US20060100242 4-(2-Phenylsulfanyl-phenyl)-piperidine derivates as serotonin reuptake inhibitors |
| 05/11/2006 | US20060100241 Method for enhancing mutant protein activity |
| 05/11/2006 | US20060100240 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 05/11/2006 | US20060100239 Method for producing optically active amines |
| 05/11/2006 | US20060100238 4',7-Dihydroxyisoflavanone (phenyl)hydrazone; 4,7-Dihydroxyisoflavanone(4,7-dihydroxyisoflavanone)hydrazone; anticarcinogenic and antiinflammatory agents; cyclooxygenase inhibitor |
| 05/11/2006 | US20060100237 Excitatory amino acid receptor antagonists |
| 05/11/2006 | US20060100236 5-HT4 receptor agonist compounds |
| 05/11/2006 | US20060100235 Pharmaceutical use of substituted 1,2,4-triazoles |
| 05/11/2006 | US20060100234 Gastric protection and gastric acid secretion-inhibitors; antiulcer agents; acid reflux, Zollinger-Ellison syndrome, heartburn and peptic ulcer bleeding; e.g. methyl 8-(2,3-dihydro-2-hydroxy-1-indenylamino)-2,3- dimethyl-imidazo(1,2a)pyridine-6-carboxylate |
| 05/11/2006 | US20060100233 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 05/11/2006 | US20060100232 Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof |
| 05/11/2006 | US20060100231 Amorphous clopidogrel hydrogen sulfate |
| 05/11/2006 | US20060100230 Indolin phenylsulfonamide derivatives |
| 05/11/2006 | US20060100229 Pyrazolopyridines and analogs thereof |
| 05/11/2006 | US20060100228 Sulfonamide-containing benzene derivatives; cancer and inflammatory, immunomodulatory or respiratory diseases |
| 05/11/2006 | US20060100227 Pyrimidine derivaties |
| 05/11/2006 | US20060100226 2-Thiopyrimidinones as therapeutic agents |
| 05/11/2006 | US20060100225 Heteroaryl guanidines; inhibitors of viral replication |
| 05/11/2006 | US20060100224 Piperidine ouracil used as a medicament for treating bacterial infections |
| 05/11/2006 | US20060100223 Quinazoline derivatives and pharmaceutical compositions containing them |
| 05/11/2006 | US20060100222 Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes |
| 05/11/2006 | US20060100221 5-[[(2,3-Difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl) 1 methylethyl]amino]-thiazolo[4,5-d]pyrimidin-2(3H)-one; asthma and allergic diseases, autoimmune pathologies such as rheumatoid arthritis and atherosclerosis |
| 05/11/2006 | US20060100219 Dihydroimidazoles and tetrahydropyrmidines containing amide and sulfonamide groups, e.g., 3-[(2,3-Dichlorobenzenesulphonyl)methylamino]-N-{2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]ethyl}-N-methylpropionamide; treating pain, skin disease, irritable bladder or colon, asthma, COPD, and stomach inflammation |
| 05/11/2006 | US20060100218 Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline |
| 05/11/2006 | US20060100216 Novel B1 bradykinin receptor antagonists |
| 05/11/2006 | US20060100215 8A,9-dihydro-4aH-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents |
| 05/11/2006 | US20060100214 Fast dissolving and taste masked oral dosage form comprising sildenafil |
| 05/11/2006 | US20060100213 Triazoles and methods of use |
| 05/11/2006 | US20060100212 fewer side effects; 2-keto-oxadiazole derivatives; 7-phenyl-1-[5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl]-heptan-1-one; |
| 05/11/2006 | US20060100211 2-(3,4-dichlorophenylamino)-4-thiocyanato-5-nitro-pyrimidine; 2-chloro-4-(2-acetylamino-ethylamino)-5-trifluoromethyl-pyrimidine; lung cancer |
| 05/11/2006 | US20060100210 Methods for treatment of scleroderma |
| 05/11/2006 | US20060100209 Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| 05/11/2006 | US20060100208 Pyrazole derivatives as cannabinoid receptor antagonists |
| 05/11/2006 | US20060100207 Dihydropyridinone derivatives |
| 05/11/2006 | US20060100206 Heterocyclic CB1 receptor antagonists |
| 05/11/2006 | US20060100205 Compositions for affecting weight loss |
| 05/11/2006 | US20060100204 Anti-cytokine heterocyclic compounds |
| 05/11/2006 | US20060100202 Novel compounds |
| 05/11/2006 | US20060100201 5-Cyano-furan-2-carboxylic acid (4-morpholin-4-yl-2-piperidin-1-yl-phenyl)-amide; selective and potent protein tyrosine kinase inhibitors providing inhibition of c-fms kinase; treating autoimmune diseases and diseases with an inflammatory component; treating metastasis from ovarian, breast cancer |
| 05/11/2006 | US20060100200 Selective oxidation of the the N-atom of the quinoline group using a peroxomonosulfuric acid, peroxodisulfuric acid or their salts in the presence of a ketone; N-atoms of the 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one scaffold are not oxidized |
| 05/11/2006 | US20060100199 Novel condensed imidazole derivatives |
| 05/11/2006 | US20060100198 Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-ce]indol-6-one |
| 05/11/2006 | US20060100197 7,8,9,10-Tetrahydropyrido[2,3-b]azocine derivatives; CCR5 chemokine receptor antagonists; prophylactic for lymphadenopathy associated and/or human T-cell leukemia/lymphoma virus infections in peripheral mononuclear blood cells; AIDS; quaternization, oxidation, condensation, deprotecting, amidation |
| 05/11/2006 | US20060100196 Substituted amines for the treatment of alzheimer's disease |
| 05/11/2006 | US20060100195 Remedies for urinary frequency |
| 05/11/2006 | US20060100194 Lactam compounds useful as protein kinase inhibitors |
| 05/11/2006 | US20060100193 Factor Xa inhibitors |
| 05/11/2006 | US20060100192 Heteroaryl diazacycloalkanes, their preparation and use |
| 05/11/2006 | US20060100191 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator |
| 05/11/2006 | US20060100190 Motexafin lutetium phototherapy with low fluences for treating vascular inflammation |
| 05/11/2006 | US20060100189 Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux |
| 05/11/2006 | US20060100188 Treatment methods |
| 05/11/2006 | US20060100187 Synergistic combinations of macrolide t-cell modulator or immunosuppressant and a retinoid |
| 05/11/2006 | US20060100186 Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| 05/11/2006 | US20060100185 5-Androsten-3beta-ol steroid intermediates and processes for their preparation |
| 05/11/2006 | US20060100184 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 05/11/2006 | US20060100183 Therapeutic agents targeting the NCCa-ATP channel and methods of use thereof |
| 05/11/2006 | US20060100182 Pharmaceutical compositions for the treatment of urinary incontinence |
| 05/11/2006 | US20060100181 Combinations for the treatment of inflammatory skin disorders |
| 05/11/2006 | US20060100180 Composition containing an androgenous 11b-halogen steroid and a progestational hormone, and male contraceptive based on said composition |
| 05/11/2006 | US20060100179 Compositions and methods for use in targeting vascular destruction |
| 05/11/2006 | US20060100178 Dermal agent |
| 05/11/2006 | US20060100177 Stabilized ascorbic acid derivatives |
| 05/11/2006 | US20060100176 Carboxylic acid diesters, methods for the production thereof and methods for the production of pharmaceutical active substances coupled to free amino groups with polysaccharide or polysaccharide derivatives |
| 05/11/2006 | US20060100175 Novel therapeutic use of low molecular weight heparins |
| 05/11/2006 | US20060100174 Configuration of glycosaminoglycans |
| 05/11/2006 | US20060100173 Ophthalmic solution |
| 05/11/2006 | US20060100172 Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type II diabetes |
| 05/11/2006 | US20060100171 Branched alpha-glucans for weight management |
| 05/11/2006 | US20060100170 Isopycnic pharmaceutical formulation |
| 05/11/2006 | US20060100169 Method to reduce an inflammatory response from arthritis |
| 05/11/2006 | US20060100168 Method of treating cancer using adenosine and its analogs |
| 05/11/2006 | US20060100167 Methods and compositions for the treatment of autoimmune disorders using clofarabine |
| 05/11/2006 | US20060100166 Compounds for modulating the activity of exchange proteins directly activated by camp (epacs) |
| 05/11/2006 | US20060100165 aqueous emulsion for the treatment of rosacea skin disorders, acne, dermatitis; Glycerol, Isopropyl palmitate, Cetyl alcohol, Stearyl monostearate, Oleyl alcohol, Ceteareth-20; good cosmetic properties and long shelf-life with minimum of 2 years |
| 05/11/2006 | US20060100164 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal |
| 05/11/2006 | US20060100163 Oligosaccharides linked by amide, imine,ether, ester, carbonate, carbamate, urea, thioester bond to active agent produce hydrophilicity; easily produced with homogeneity, predictable, desirable pharmacokinetic profile, enhanced biocompatibility |
| 05/11/2006 | US20060100162 Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
| 05/11/2006 | US20060100161 Mitotic kinesin inhibitors and methods of use thereof |
| 05/11/2006 | US20060100159 Preventing desensitization of receptors |
| 05/11/2006 | US20060100157 Novel use of peptide compounds for treating pain in painful diabetic neuropathy |
| 05/11/2006 | US20060100155 Method for the therapeutic management of endometriosis |
| 05/11/2006 | US20060100152 Methods and compositions in treating pain and painful disorders using 9949, 14230, 760, 62553, 12216, 17719, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 16314, 1613, 1675, 9569 or 13424 molecules |
| 05/11/2006 | US20060100150 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| 05/11/2006 | US20060100148 Glutathione-S-transferase tag, hexahistidine tag, maltose binding protein tag, haemagglutinin tag, and cellulose binding protein; for treating and preventing Flaviviridae virus (e.g., hepatitis C virus) infections |
| 05/11/2006 | US20060100146 AWAT-related methods and articles |
| 05/11/2006 | US20060100140 Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]2-methylphenyl}-4- (3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia |
| 05/11/2006 | US20060100139 Pharmaceutical used for treating HIV infection, the composition and uses thereof |
| 05/11/2006 | US20060100136 Synergistic effects of combined administration of mirtazapine and a stimulant compound |